Ibogaine

On Saturday, President Donald Trump signed an executive order directing the U.S. Food and Drug Administration to move faster on reviews tied to psychedelic-based research and treatment, including ibogaine that veteran advocates say may help post-traumatic stress disorder. The push on mental health...

Known as the "Psychedelic Concierge to The Stars," Zappy Zapolin has teamed up with Universal Ibogaine (TSXV: IBO) to help bring this important substance to the masses. Ibogaine is an African root considered the only legitimate addiction interrupter capable of breaking a heroin, meth,...

MindMed Inc. (NASDAQ: MNMD) reported favorable results for one of its proprietary compounds. The Phase 1 trial of MM-110 included 108 healthy volunteers and was designed to study the pharmacokinetics and neurocognitive effects of the substance, ensuring its safety and tolerability. MM-110 is...

The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics to study a non-hallucinogenic version of the psychedelic drug ibogaine.   Collaboration with the National Institute...

Novamind Inc. (OTCQB: NVMDF) a mental health company specializing in psychedelic medicine, recently announced a strategic investment and advisory agreement with Bienstar Wellness Corp, an Uruguay-based mental health company, to assist in the expansion of Latin America's first network of...

Psychedelic use may provide a window of opportunity to kick drug addiction, according to a recent study. Following bleak mortality data published this week by the U.S. Centers for Disease Control that saw national overdose deaths exceeding 100,000 for the first time over a 12 month period, a new...